EMA Authorised: Opdualag (nivolumab;relatlimab) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

Opdualag, a nivolumab and relatlimab combination, has been authorised for melanoma in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Opdualag (relatlimab and nivolumab)

Snippet

Status: Authorised. Therapeutic area: Melanoma. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 11/06/2026